Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 6/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.36 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5210068 | 0.81 | HRH4 (0.40) | GSK3BCDK2CDK4CDC7MAPK9 | |
| SCHEMBL6106207 | 0.81 | GSK3B (0.40) | GSK3BCDK2MKNK1MAPK14MAPK13 | |
| SCHEMBL5210816 | 0.80 | HRH4 (0.41) | GSK3BCDK2CDK4EIF2AK2FLT3 | |
| SCHEMBL5208309 | 0.79 | MKNK1 (0.46) | GSK3BCDK2MKNK1MAPK14MAPK13 | |
| Pyridine SCHEMBL5210420 | 0.79 | HRH4 (0.36) | GSK3BCDK2MKNK1CDK4CDC7 | |
| SCHEMBL6107018 | 0.75 | GSK3B (0.44) | GSK3BCDK2 | |
| SCHEMBL5210551 | 0.74 | MAPK9 (0.49) | LCKGSK3BCDK2MAPK14MAPK13 | |
| SCHEMBL5875554 | 0.74 | GSK3B (0.48) | GSK3BCDK2MKNK1MAPK14MAPK13 | |
| SCHEMBL5208591 | 0.74 | CDK4 (0.54) | GSK3BCDK2MAPK14CDK4MAPK9 | |
| SCHEMBL5875691 | 0.73 | MAPK14 (0.61) | GSK3BMKNK1MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453830-B1 | PYRAZOLO-PYRIDINE DERIVATIVES AS ANTIHERPES AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-09-12 | — | — | EP | claimed |
| US-7199120-B2 | Pyrazolo-pyridine derivatives as antiherpes agents | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-03 | — | — | US | claimed |
| US-20040248903-A1 | Pyrazolo-pyridine derivatives as antiherpes agents | SMITHKLINE BEECHAM CORPORATION | 2004-12-09 | — | — | US | claimed |
| EP-1453830-B1 | PYRAZOLO-PYRIDINE DERIVATIVES AS ANTIHERPES AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070161653-A1 | Pyrazolo-Pyridine Derivatives As Antiherpes Agents | GUDMUNDSSON KRISTJAN | 2007-07-12 | — | — | US | disclosed |
| US-20070161653-A1 | Pyrazolo-Pyridine Derivatives As Antiherpes Agents | GUDMUNDSSON KRISTJAN | 2007-07-12 | — | — | US | disclosed |
| US-20070161653-A1 | Pyrazolo-Pyridine Derivatives As Antiherpes Agents | GUDMUNDSSON KRISTJAN | 2007-07-12 | — | — | US | disclosed |
| US-7199120-B2 | Pyrazolo-pyridine derivatives as antiherpes agents | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199120-B2 | Pyrazolo-pyridine derivatives as antiherpes agents | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199120-B2 | Pyrazolo-pyridine derivatives as antiherpes agents | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-20040248903-A1 | Pyrazolo-pyridine derivatives as antiherpes agents | SMITHKLINE BEECHAM CORPORATION | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161653-A1 | Pyrazolo-Pyridine Derivatives As Antiherpes Agents | HRH4, HRH2, HRH1 | LCK 1145/4885GSK3B 3007/4885CDK2 625/4885 |
| US-20040248903-A1 | Pyrazolo-pyridine derivatives as antiherpes agents | HRH4, HRH1, HRH2 | LCK 1007/4885GSK3B 2956/4885CDK2 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.